CoChat

Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems

Open access
Jiménez-Gómez, Yolanda, Alba-Molina, David, Blanco-Blanco, Mario, Pérez-Fajardo, Lorena, Reyes-Ortega, Felisa, Ortega-Llamas, Laura, Villalba-González, Marta, Fernández-Choquet de Isla, Ignacio, Pugliese, Francisco, Stoikow, Indira, González-Andrades, Miguel · 2022 · Pharmaceutics

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Abstract

In recent years, the number of patients with ocular diseases is increasing as a consequence of population aging. Among them, one of the most common is the age-related macular degeneration (AMD), a condition that leads to vision loss if it is not treated. AMD is a multifactorial disorder with two advanced forms, dry and neovascular AMD. Currently, although there is no approved therapy that significantly impacts dry AMD progression, several pharmacologic therapies exist for neovascular AMD. Notwithstanding, evidence suggests a suboptimal result in a high number of patients receiving these therapeutic options. Consequently, finding effective strategies is not only a still unmet medical need in dry AMD but also in neovascular AMD. This underlines the need for new drug delivery technologies that can improve the pharmacological action and drug concentration at the target sites. In this regard, sustained drug delivery systems are presented as the most promising therapeutic options in AMD patients. This review summarized the pathogenesis and the current treatment options for AMD, focusing on the emerging ocular sustained drug delivery approaches undergoing clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics14071473

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic illustration of eye anatomy and drug delivery systems in Age-Related Macular Degeneration. dAMD: dry Age-Related Macular Degeneration; nAMD: neovascular Age-Related Macular Degeneration; DDS: Drug Delivery Systems.
Figure 1 Schematic illustration of eye anatomy and drug delivery systems in Age-Related Macular Degeneration. dAMD: dry Age-Related Macular Degeneration; nAMD: neovascular Age-Related Macular Degeneration; DDS: Drug Delivery Systems.CC BY · PubMed Central
Figure 2 Schematic illustration of emerging sustained drug delivery systems for Age-Related Macular Degeneration in Clinical Trials. CNTF: Ciliary Neurotrophic Factor; PDS: Port Delivery System.
Figure 2 Schematic illustration of emerging sustained drug delivery systems for Age-Related Macular Degeneration in Clinical Trials. CNTF: Ciliary Neurotrophic Factor; PDS: Port Delivery System.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Research works printed but not linked: 1

  1. Damian, 2006, Epidemiology of age-related macular degeneration. Situation in Spain, Aten. Primaria, 38, 51

Cited by

See all 19

Metadata

Authors
Jiménez-Gómez, Y., Alba-Molina, D., Blanco-Blanco, M., Pérez-Fajardo, L., Reyes-Ortega, F., Ortega-Llamas, L., Villalba-González, M., Fernández-Choquet de Isla, I., Pugliese, F., Stoikow, I., & González-Andrades, M.
Affiliations
  • Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Department of Ophthalmology, Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
  • Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2022-07-15
Volume
14
Issue
7
Pages
1473
ISSN
1999-4923 (ISSN-L)
OpenAlex
W4285733205
Cited by
19
References
71
Citations by year
2026: 4 · 2025: 7 · 2024: 5 · 2023: 3
FWCI
0.33
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, PAIDI2020)
  • Consejería de Salud y Familias, Junta de Andalucía, co-funded by Fondo Social Europeo de Andalucía (ERDF/ESF, PAIDI2020)
  • Plan Andaluz de Investigación, Desarrollo e Innovación (ERDF/ESF, PAIDI2020)
  • Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía co-funded by Fondo Social Europeo de Andalucía (ERDF/ESF, PAIDI2020)
  • Consejería de Salud y Familias, Junta de Andalucía (ERDF/ESF, PAIDI2020)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
age-related macular degeneration, sustained drug release, dry age-related macular degeneration, neovascular AMD, ocular drug delivery, anti-VEGF therapy, AMD pathogenesis, clinical trials, vision loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems. https://app.cochat.ai/papers/10.3390/pharmaceutics14071473
The paper
Jiménez-Gómez, Y., Alba-Molina, D., Blanco-Blanco, M., Pérez-Fajardo, L., Reyes-Ortega, F., Ortega-Llamas, L., Villalba-González, M., Fernández-Choquet de Isla, I., Pugliese, F., Stoikow, I., & González-Andrades, M. (2022). Novel Treatments for Age-Related Macular Degeneration: A Review of Clinical Advances in Sustained Drug Delivery Systems. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14071473

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.